[Use of calcium carbonate (CaCO3) as phosphate binder in dialysis patients in long-term follow-up over 3 years].
In 26 dialysis patients (age 46 +/- 47.8 years, dialysis 20.1 +/- 57 months) calcium carbonate was introduced to phosphate reduction for 3 years. The use of CaCO3 (4.4-9 g/d) for 9 months did reduce the phosphate level from 2.51 to 1.51 mmol/l in 77% of the patients and increase the calcium from 2.23 to 2.47 mmol/l. The long-term use use up to 3 years did'nt reduce the phosphate level effectively (mean value 2.24 mmol/l). In 77% of the patients a progression and in 42% new calcifications could be observed. The percentage of patients with soft tissue calcification within the 3-year CaCO3 therapy was increased from 43% to 67%. Therefore, CaCO3 alone in unsuitable for long-term use as phosphate binder in dialysis patients.
Sperschneider
H
H
Nephrologische Abteilung, Friedrich-Schiller-Universität Jena.
Günther
K
K
Stein
G
G
Marzoll
I
I
Kirchner
E
E
D000535:Aluminum / Q000097:blood; D002118:Calcium / Q000097:blood; D002119:Calcium Carbonate / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood*; D008134:Long-Term Care; D008297:Male; D008875:Middle Aged; D010710:Phosphates / Q000097:blood*; D006435:Renal Dialysis
D010710:Phosphates; D000535:Aluminum; D002119:Calcium Carbonate; D002118:Calcium
Untersuchungen zum Einsatz von Calciumcarbonat (CaCO3) als Phosphatbinder bei Dialysepatienten im Langzeitverlauf über 3 Jahre.